Heparin

Generic Name
Heparin
Brand Names
Heparin Leo
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
9005-49-6
Unique Ingredient Identifier
T2410KM04A
Background

Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.

Indication

Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.

Associated Conditions
Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
Associated Therapies
Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2013-04-04
Last Posted Date
2021-10-21
Lead Sponsor
University Hospital, Montpellier
Target Recruit Count
94
Registration Number
NCT01823393
Locations
🇫🇷

Montpellier University Hospital, Montpellier, France

Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma

First Posted Date
2013-01-23
Last Posted Date
2022-02-16
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
13
Registration Number
NCT01773083
Locations
🇳🇱

Academic Medical Center, Amsterdam, Noord-Holland, Netherlands

🇳🇱

Maasstad Hospital, Rotterdam, Zuid-Holland, Netherlands

🇧🇪

University Hospital, Gent, Gent, Oost-Vlaanderen, Belgium

and more 5 locations

BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.

First Posted Date
2012-09-28
Last Posted Date
2014-10-01
Lead Sponsor
Shenyang Northern Hospital
Target Recruit Count
2194
Registration Number
NCT01696110
Locations
🇨🇳

1 st Hosp. of Anhui Med Univ., Hefei, Anhui, China

🇨🇳

Anhui Provincial Hosp., Hefei, Anhui, China

🇨🇳

3rd Hosp. of Beijing Univ., Beijing, Beijing, China

and more 78 locations

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Phase 1
Conditions
Interventions
First Posted Date
2012-07-30
Last Posted Date
2012-08-13
Lead Sponsor
Azidus Brasil
Target Recruit Count
44
Registration Number
NCT01652638
Locations
🇧🇷

LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, Brazil

PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS

Phase 1
Conditions
Interventions
First Posted Date
2012-07-27
Last Posted Date
2012-08-13
Lead Sponsor
Azidus Brasil
Target Recruit Count
60
Registration Number
NCT01651923
Locations
🇧🇷

LAL Clínica Pesquisa e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

First Posted Date
2012-07-27
Last Posted Date
2017-04-07
Lead Sponsor
The Medicines Company
Target Recruit Count
803
Registration Number
NCT01651780
Locations
🇨🇦

Montreal Heart Institute, Montreal, Quebec, Canada

🇨🇦

St. Paul´s Hospital Providence Health Care, Vancouver, Canada

🇫🇷

Centre Hospitalier de Lyon, Bron, France

and more 30 locations

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-07-24
Last Posted Date
2014-07-10
Lead Sponsor
University of Manitoba
Target Recruit Count
76
Registration Number
NCT01648036
Locations
🇨🇦

Hopital de l'Enfant-Jesus, Quebec, Canada

🇨🇦

Ottawa Hospital General Campus, Ottawa, Ontario, Canada

🇨🇦

St Michael's Hospital, Toronto, Ontario, Canada

and more 6 locations

Heparin Dose for Radial Angiography

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-07-06
Last Posted Date
2012-07-06
Lead Sponsor
University of Alberta
Target Recruit Count
49
Registration Number
NCT01634438
Locations
🇨🇦

Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

First Posted Date
2012-05-31
Last Posted Date
2021-07-29
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
152
Registration Number
NCT01608906
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

Understanding "Heparin Resistance" in Cardiac Surgery

First Posted Date
2012-05-15
Last Posted Date
2016-12-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
504
Registration Number
NCT01598883
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath